Synergistic mobilization of hemopoietic progenitor cells using concurrent beta1 and beta2 integrin blockade or beta2-deficient mice.
The hierarchy of cytoadhesion molecules involved in hematopoietic/stem progenitor cell mobilization has not yet been delineated. Previous studies have suggested an important role for alpha4beta1 integrin in this process. To test whether mobilization involves dynamic interactions of alpha4beta1 with other integrins on hematopoietic cells, especially the beta2 integrins, mice and primates were treated with anti-beta1 or anti-beta2 antibodies alone or in combination. A single injection of anti-alpha4beta1 antibody elicited reproducible mobilization in contrast to other antibodies, and 3 injections yielded higher mobilization efficiency than each of the other antibodies. When the anti-beta2 (anti-CD11a or anti-CD18) or anti-alpha5/beta1 integrin antibody was combined with anti-alpha4, an augmentation in mobilization was seen that was either additive or synergistic, depending on the potency of the antibody used. Synergy between anti-alpha4 and anti-CD18 (beta(2)) antibody blockade was seen in primates and confirmed in anti-alpha4-treated CD18-deficient mice. In the latter, there was a 49-fold increase in mobilization with anti-alpha4, much higher than in littermate control animals, in CD18 hypomorphic mice, or in other strains of mice tested. Data from both the antibody blockade and gene-targeted mice suggest that the cooperativity of alpha4beta1 with beta2 integrins becomes evident when they are concurrently inhibited. It is unclear whether this cooperativity is exerted at the stage of reversible adhesion versus migration, and enhancement of and whether the 2 integrins work in a sequential or parallel manner. Whatever the mechanism, the data provide a novel example of beta1 and beta2 integrin crosstalk in stem/progenitor cell mobilization.
Papayannopoulou
T
T
Division of Hematology, University of Washington, Seattle, WA 98195-7710, USA. thalp@u.washington.edu
Priestley
G V
GV
Nakamoto
B
B
Zafiropoulos
V
V
Scott
L M
LM
Harlan
J M
JM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000166:cytology; D018821:CD18 Antigens / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D016207:Cytokines / Q000097:blood / Q000187:drug effects; D004357:Drug Synergism; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D039041:Integrin alpha4beta1; D019012:Integrin beta1 / Q000276:immunology / Q000494:pharmacology*; D016023:Integrins / Q000276:immunology; D008251:Macaca; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D016201:Receptors, Lymphocyte Homing / Q000276:immunology
D000911:Antibodies, Monoclonal; D018821:CD18 Antigens; D016207:Cytokines; D039041:Integrin alpha4beta1; D019012:Integrin beta1; D016023:Integrins; D016201:Receptors, Lymphocyte Homing